CAR T CELL THERAPY MARKET ANALYSIS

CAR T Cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI102
Pages :222
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Global CAR T Cell Therapy market- Key Players

Major players operating in the global CAR T cell therapy market include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.

Car T Cell Therapy Market Report Snapshots